Call Us @ 0172 - 4680800 | info@indswift.com | NSE - BSE
More evidence supports link between orthostatic hypotension and CVD
 
The team analyzed data from 9,139 participants ages 45 to 64 who enrolled in the long-running Atherosclerosis Risk in Communities (ARIC) Study between 1987 and 1989. These participants were followed for cardiovascular events and mortality through Dec. 31, 2015.
"OH was associated with all measures of subclinical cardiovascular disease and was an important predictor of clinical CVD events in the future," said Stephen Juraschek, MD, PhD, Instructor of Medicine at BIDMC and Harvard Medical School. "When orthostatic hypotension is detected in middle-aged adults who do not have known cardiovascular disease, health care practitioners should be mindful of undetected heart disease."
Juraschek and colleagues' findings appeared online in theJournal of the American Heart Association on May 7.
"While there is controversy surrounding the association between OH and cardiovascular disease, our findings were unequivocal and consistent," said Juraschek. "These findings strongly support our hypothesis about OH being an important manifestation of undetected CVD. Many treatments for OH such as increasing sodium intake or stopping blood pressure medications have the potential to worsen blood pressure control and risk for CVD. Clinicians should be aware of the possibility that undiagnosed CVD may be present in adults with OH prior to starting treatments."

(Sciencedaily)
 
Other Related News:
Researchers develop reversible antiplatelet therapy to fight clotting, cancer metastasis
New insight into cell receptors opens the way for tailored cancer drugs
Pricing concerns will be the leading roadblock for pharma growth in 2019
Scientists develop tool to measure success of HIV cure strategies
High blood pressure linked to zinc deficiency
Generic Version of Popular Asthma Inhaler Wins FDA Approval
Beware of evening stress
Severe shortage of antibiotic eye drops & vitamin C tablets across India as these products brought under price control
Oncolytics Biotech initiates phase 2 study combining Pelareorep and Keytruda in advanced pancreatic cancer
NIH scientists illuminate causes of hepatitis b virus-associated acute liver failure